IL-1β and IL-18: inflammatory markers or mediators of hypertension?

S M Krishnan, C G Sobey, E Latz, A Mansell and G R Drummond

1Department of Pharmacology, Monash University, Clayton, Vic, Australia, 2Department of Surgery, Monash Medical Centre, Southern Clinical School, Monash University, Clayton, Vic, Australia, 3Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany, 4Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA, 5German Center for Neurodegenerative Diseases, Bonn, Germany, and 6Centre for Innate Immunity and Infectious Diseases, MIMR-PHI Institute of Medical Research, Clayton, Vic, Australia

Chronic inflammation in the kidneys and vascular wall is a major contributor to hypertension. However, the stimuli and cellular mechanisms responsible for such inflammatory responses remain poorly defined. Inflammasomes are crucial initiators of sterile inflammation in other diseases such as rheumatoid arthritis and gout. These pattern recognition receptors detect host-derived danger-associated molecular patterns (DAMPs), such as microcrystals and reactive oxygen species, and respond by inducing activation of caspase-1. Caspase-1 then processes the cytokines pro-IL-1β and pro-IL-18 into their active forms thus triggering inflammation. While IL-1β and IL-18 are known to be elevated in hypertensive patients, no studies have examined whether this occurs downstream of inflammasome activation or whether inhibition of inflammasome and/or IL-1β/IL-18 signalling prevents hypertension. In this review, we will discuss some known actions of IL-1β and IL-18 on leukocyte and vessel wall function that could potentially underlie a prohypertensive role for these cytokines. We will describe the major classes of inflammasome-activating DAMPs and present evidence that at least some of these are elevated in the setting of hypertension. Finally, we will provide information on drugs that are currently used to inhibit inflammasome/IL-1β/IL-18 signalling and how these might ultimately be used as therapeutic agents for the clinical management of hypertension.

Abbreviations
AP-1, activator protein-1; CRP, C-reactive protein; DAMP, danger-associated molecular pattern; eNOS, endothelial NOS; IL-18BP, IL-18 binding protein; IL-18Rα, IL-18 receptor α chain; IL-1Ra, IL-1 receptor antagonist; IL-1RI, IL-1 receptor type I; IL-1RII, IL-1 receptor type II; NLR, NOD-like receptor; NOX, NADPH oxidase; PAMP, pathogen-associated molecular pattern; PRR, pattern recognition receptor; ROS, reactive oxygen species; Th1, T-helper 1; Th17, T-helper 17; VSMC, vascular smooth muscle cell
Introduction

Hypertension is associated with chronic inflammation in key tissues and organs involved in the regulation of BP such as the kidneys and blood vessels. Renal inflammation results in glomerular injury and impaired sodium urinary excretion, while inflammation in the vasculature can contribute to impaired endothelial function, resistance and stiffening, all of which are key factors involved in the development of hypertension (Ross, 1999; Pauletto and Rattazzi, 2006; Rodriguez-Iturbe et al., 2012). The signalling platforms known as inflammasomes have emerged as crucial initiators of inflammation in response to diverse pathogen- and host-derived danger signals. The primary function of inflammasomes is to activate the cysteine protease, caspase-1, which in turns processes the proinflammatory IL-1 family cytokines IL-1β and IL-18 from their inactive to active forms (Schroder and Tschopp, 2010a). While it is clear that circulating levels of IL-1β and IL-18 are increased in hypertension (Dalekos et al., 1997; Rabkin, 2009), to date, no studies have examined whether this occurs downstream of inflammasome and caspase-1 activation. It is also not known whether inhibition of the production or actions of IL-1β and/or IL-18 reduces renal and vascular inflammation and thereby affords protection in hypertension. This review will highlight the role that IL-1β and IL-18 play as early initiators of inflammation. Furthermore, we will describe what inflammasomes are and present evidence for why they might be considered as important mediators of renal and vascular inflammation in hypertension, and thus potential targets for future antihypertensive therapies.

Renal and vascular inflammation in hypertension

Hypertension is a major risk factor for the two leading causes of death worldwide, ischaemic heart disease and stroke (WHO, 2013). It is widely accepted that chronic overactivation of the renin-angiotensin-aldosterone system is a major contributor to hypertension (Weir and Dzau, 1999). The actions of angiotensin II on AT_{1} receptors expressed on resident cells of blood vessels, kidneys and the CNS are responsible for its ‘classical’ prohypertensive actions, including vasoconstriction, increased vascular superoxide production, enhanced sodium reabsorption and elevated sympathetic activity (Palatini, 2001; Levy, 2004; Probstfield and O’Brien, 2010). However, it has recently been shown that angiotensin II may contribute to renal and vascular inflammation by inducing the activation and accumulation of leukocytes in the kidneys and artery wall respectively (Johnson et al., 1992; Haller et al., 1997; Suzuki et al., 2003; Rodriguez-Iturbe et al., 2004; Guzik et al., 2007).

Chronic low-grade inflammation appears to play an important role in the pathogenesis of hypertension. In hypertensive patients and in animal models, there is increased activity of the prototypic transcription factor, NF-κB (Ruiz-Ortega et al., 2001; Zhou et al., 2010a), which leads to increased tissue and/or circulating levels of proinflammatory mediators including the acute phase protein, C-reactive protein (CRP) (Bautista, 2003), adhesion molecules including intercellular adhesion molecule 1 and vascular cell adhesion molecule 1, chemokines, such as CCL2 (MCP-1) and CCL5 (RANTES) (Mervaala et al., 1999; Dorfmuller et al., 2003; Boulbou et al., 2005; Madej et al., 2005; Chan et al., 2012), and proinflammatory cytokines such as IL-6, TNF-α (Gu et al., 2006; Zhang et al., 2012) and, of direct relevance to the current review, IL-1β and IL-18 (Dalekos et al., 1997; Rabkin, 2009). Furthermore, numerous studies have shown that by blocking the actions of several of the above mediators either by genetic deletion or pharmacological inhibition, it is possible to reduce disease parameters in hypertension. For example, mice lacking IL-6 display a blunted increase in systolic BP and a reduction in renal damage and fibrosis compared with wild-type mice following induction of hypertension by acute stress or the infusion of angiotensin II (Lee et al., 2004; 2006; Zhang et al., 2012). Chemokine recep-
IL-1β and IL-18 are elevated in hypertension and are potential mediators of renal and vascular inflammation

IL-1β and IL-18 are members of the proinflammatory IL-1 cytokine superfamily (Dinarello, 2002). The major cellular sources of IL-1β and IL-18 are monocytes and macrophages (Kahlenberg and Dubjak, 2004; Dinarello et al., 2013), however other cell types, such as vascular endothelial cells and renal tubular epithelial cells, may also generate these cytokines under certain conditions (Ald et al., 1992; Dewberry et al., 2000; Striz et al., 2005). The proinflammatory actions of IL-1β and IL-18 are achieved by stimulation of their specific cell surface receptors, namely the IL-1 type 1 receptor (IL-1RI) and the IL-18 receptor α chain (IL-18Rα) respectively (Dinarello, 2002). These receptors are found on several leukocyte subsets relevant to renal and vascular inflammation in hypertension. These include immune cells, such as lymphocytes, monocytes and macrophages, constitutive cell types of the vessel wall, such as vascular endothelial cells and vascular smooth muscle cells (VSMCs), as well as cells in the kidney such as renal endothelial cells and tubular epithelial cells (Nakamura et al., 2000; Gerdes et al., 2002; Miyacuchi et al., 2009). Both receptors are members of the immunoglobulin superfamily and display remarkable similarities in terms of their amino acid sequences, overall architecture and the signal transduction mechanisms they utilize (O’Neill, 2002; Sims, 2002).

The binding of IL-1β and IL-18 to their receptors causes the recruitment of distinct yet highly homologous accessory proteins, which facilitate high-affinity binding between the ligand-receptor complex. For the IL-1β/IL-1RI complex, the relevant accessory protein is termed IL-1RacP, whereas for the IL-18/IL-18Rα complex is IL-18Rβ (Figure 1) (Sims, 2002; Arend et al., 2008). The binding of accessory proteins to IL-1RI and IL-18Rβ also initiates the recruitment of several adapter molecules to the cytoplasmic domains of the receptors. Such adapter molecules include myeloid differentiation factor 88, IL-1R-associated kinase and TNF receptor-associated factor 6 (Figure 1) (Thomassen et al., 1998; Arend et al., 2008). These in turn activate signal transduction pathways involving the kinases, JNK and p38 MAPK, as well as transcription factors such as NF-kB and activator protein-1 (AP-1) (Thomassen et al., 1998; Arend et al., 2008) which are renowned for inducing a proinflammatory gene expression profile in various cell types.

IL-33 is a more recently identified member of the IL-1 family (Arend et al., 2008). In contrast to IL-1β and IL-18, it is the uncleaved form of IL-33 that is active. Moreover, IL-33 triggers an anti-inflammatory type 2 immune response when it binds to its receptor, ST2, which results in the release of cytokines such as IL-5 and IL-13 (Pei et al., 2014). While recent studies have suggested a possible protective role of IL-33/ST2 signalling in other cardiovascular diseases such as heart failure and atherosclerosis (Miller and Liew, 2011; Januzzi, 2013), to date no studies have investigated the role of IL-33 in hypertension.

It is important to note that the actions of IL-1β and IL-18 in a given tissue are governed not only by their concentrations within that tissue and the expression profile of their respective receptors, but also by the presence of several inhibitor molecules that exist for each cytokine (Figure 1). For IL-1β, these include the decoy receptor, IL-1R type II (IL-1RII), which is similar in structure to the extracellular domain of the IL-1RI, however, it has a very short cytoplasmic tail and thus lacks the ability to stimulate intracellular transduction mechanisms (Dinarello, 1996; Schroder and Tschopp, 2010a). Furthermore the IL-1 receptor antagonist (IL-1Ra) is another endogenous inhibitor of IL-1β. IL-1Ra occurs in two forms, one that is secreted from circulating leukocytes and another that is retained intracellularly, especially in monocytes and epithelial cells (Arend et al., 1998). Similarly, there exists an endogenous antagonist of IL-18 known as the IL-18 binding protein (IL-18BP). IL-18BP is constitutively secreted and binds to IL-18 with high affinity (400 pM), thereby neutralizing the actions of this cytokine (Dinarello et al., 2013). The experimental and clinical use of these inhibitors in inflammatory disease models are discussed in further detail later in this review.

IL-1 family cytokines are considered to be ‘early-response’ cytokines. This means that they are released in the earliest stage of an immune response and act as a trigger for a subsequent cascade of proinflammatory cytokines. IL-1β stimulates the release of IL-6 and IL-17a, while IL-18 promotes the production of IFN-γ, IL-2 and IL-12 (Labow et al., 1997; Dinarello, 2002; Cahill and Rogers, 2008; Mills et al., 2013). These downstream cytokines are associated with highly proinflammatory T-helper 1 (Th1)- and T-helper 17 (Th17)-type immune responses and there is evidence to suggest that Th1 and Th17 cells play a major role in hypertension (Shao et al., 2003; Platten et al., 2009; Madhur et al., 2010). In addition to these well-described actions on immune cells, IL-1β and IL-18 have also been shown to have direct effects on the vascular wall that might be consistent with a prohypertensive role. For example, large and resistance-like rat arteries that had undergone ex vivo incubation with IL-1β displayed impaired endothelium-dependent relaxation responses to ACh compared with vessels that were incubated with vehicle (Loughrey et al., 2003; Jimenez-Altayo et al., 2006). This effect appeared to be due to increased vascular reactive oxygen species (ROS) production, as IL-1β-treated vessels expressed higher levels of the pro-oxidant enzymes, inducible NOS and xanthine oxidase, and generated more superoxide than controls (Briones et al., 2005; Jimenez-Altayo et al., 2006). Moreover, treatment of the vessels with superoxide dismutase partially reversed the impaired relaxation response to ACh (Jimenez-Altayo et al., 2006). In a separate study on
isolated aortas from spontaneously hypertensive rats, IL-1β directly evoked contractile responses and augmented those to the α1-adrenoceptor agonist, phenylephrine (Dorrance, 2007). Together with the IL-1β-mediated impairment of endothelium-dependent vasodilatation, such increases in contractile activity could conceivably contribute to increased total peripheral vascular resistance, which is a major determinant of BP.

Although no studies have examined the effects of IL-18 on vascular tone, this cytokine has been shown in several studies to promote the proliferation and migration of VSMCs (Chandrasekar et al., 2006; Valente et al., 2012); processes that are critical to the vascular remodelling associated with and contributing to hypertension. Again these effects appeared to result from increases in NADPH oxidase (NOX)-derived ROS production and the subsequent activation of NF-κB- and AP-1-dependent signalling pathways (Valente et al., 2012). Furthermore, the proliferative response of cultured VSMCs to angiotensin II was blocked following siRNA-mediated knockdown of IL-18 (Valente et al., 2012), indicating that IL-18 may be a crucial intermediate in the pathway by which angiotensin II promotes vascular remodelling. The actions of IL-1β and/or IL-18 in mediating inflammation associated with hypertension are summarized in Figure 2.

As mentioned, there is evidence that circulating and vascular levels of IL-1β and IL-18 are elevated in hypertension. For instance, patients with essential hypertension had higher serum levels of IL-1β than normotensive controls (Dalekos et al., 1997). Furthermore, monocytes isolated from peripheral blood of hypertensive individuals generated higher amounts of IL-1β in response to ex vivo stimulation with either angiotensin II or LPS than monocytes from normotensive controls (Dörfel et al., 1999; Li et al., 2005). These findings not only suggest that monocytes from hypertensive individuals are primed for the production of IL-1β, but they also indicate that angiotensin II may directly act on monocytes to initiate the production and/or release of the cytokine. Consistent with this latter concept, angiotensin AT1 receptor antagonists inhibited IL-1β production by monocytes taken from hypertensive individuals, either when administered to patients in vivo or when pre-incubated ex vivo with cells fol-

Figure 1
Signalling pathway and endogenous antagonists of IL-1β and IL-18. Binding of IL-1β to IL-1R1 and IL-18 to IL-18Rα is facilitated by the accessory proteins IL-1RAcP and IL-18Rβ, respectively, resulting in recruitment of the adapter proteins myeloid differentiation factor 88 (MyD88), IL-1 receptor-associated kinase (IRAK) and TNF receptor-associated factor (TRAF), which then causes NF-κB activation. Endogenous inhibitory molecules also exist for both cytokines. For IL-1β, these include an IL-1R antagonist (IL-1Ra), which competes with the IL-1RI for IL-1β binding, as well as a second IL-1β receptor, IL-1RII. The membrane-bound form of IL-1RII receptor contains a short cytosolic signalling domain whereas the soluble form of IL-1RII contains only the extracellular portion of the receptor. Thus, while they bind IL-1β, they fail to support the activation of intracellular signal transduction pathways. Similarly, the actions of IL-18 are negatively regulated by a binding protein known as IL-18BP.
Caspases are cysteine proteases that are best known for their role in regulating apoptosis. However, it is now known that the primary function of some members of the caspase family is to regulate inflammation (Wolf and Green, 1999). Collectively, these proinflammatory caspases are termed group I caspases (Martinon and Tschopp, 2007). Of the 13 mammalian caspases identified, five are thought to regulate inflammation (caspases 1, 4 and 5 in humans and caspases 1, 11 and 12 in mice) (Martinon and Tschopp, 2004; 2007), with caspase-1 being the best characterized proinflammatory caspase in humans and mice. The major role of caspase-1 in inflammation is to catalyze the intracellular processing of the proinflammatory cytokines, pro-IL-1β (31 kDa) and pro-IL-18 (24 kDa) into their mature and biologically active forms, IL-1β (17.5 kDa) and IL-18 (18 kDa) respectively (Dinarello, 2002). This step is essential as it allows the cytokines to be released from the cytosol into the extracellular space where they can act in a paracrine fashion on receptors on neighbouring cells to exert their proinflammatory influence. There is some evidence that IL-1β can be activated independently of caspase-1 by neutrophil-derived serine proteases such as elastase, cathepsin G and proteinase 3. However, these pathways are likely to play a role in the maturation of the cytokine only in disease conditions associated with an increase in neutrophil infiltration (Guma et al., 2009).

Caspases are themselves synthesized as zymogens and must be cleaved in order to be activated. This is achieved by the multi-protein enzyme complexes known as inflammasomes (Petrilli et al., 2007; Schroder and Tschopp, 2010a). Inflammasomes are comprised of upstream NOD-like receptors (NLRs), which are part of the pattern recognition receptor (PRR) superfamily (Lamkanfi and Dixit, 2014). PRRs are known to play an integral role in the innate immune response (Gordon, 2002; Kanneganti et al., 2007). NLRs are auto-activated when they detect ‘pathogen-associated molecular patterns’ (PAMPs) such as conserved motifs on microbes such as LPS and flagellin (Jha and Ting, 2009). Furthermore, host-derived stress signals otherwise known as danger-associated molecular patterns (DAMPs) have also been shown to induce activation of NLRs. DAMPs that have been shown to activate NLRs include ROS such as superoxide and hydrogen peroxide (Davis and Ting, 2010; Latz, 2010; Zhou et al., 2010b), high concentrations of extracellular ATP (Mariathasan et al., 2006), hyaluronan, which is released from the extracellular matrix in response to injury (Yamasaki et al., 2009), β amyloid, the major peptide present in amyloid plaques characteristic of Alzheimer’s disease (Halle et al., 2008) and crystalline substances such as uric acid (Martinon et al., 2006), cholesterol (Duwell et al., 2010) and silica (Hornung et al., 2008), which are thought to mediate the chronic inflammatory responses in gout, atherosclerosis and silicosis respectively.

While several NLRs have been identified, information on functional significance is only available for a few of these receptors. This includes the NLRP3-, NLRP1- and IPAF-containing inflammasomes, all of which respond to a diverse...
range of stimuli (Schroder et al., 2010b). To date, the NLRP3-containing inflammasome (also known as NALP3) is the best characterized and the isoform that is reported to link inflammation to several metabolic diseases, including diabetes and atherosclerosis (De Nardo and Latz, 2011; Wen et al., 2012; Lu and Kakkar, 2014). There are three basic subunits that make up the NLRP3 inflammasome: (i) the NLRP3 protein, which consists of the basic NLR structure [leucine-rich repeats at the C-terminus, a central nucleotide-binding and oligomerization domain (NACHT) and a pyrin-domain at the N-terminus]; (ii) ASC, a heterodimeric adapter protein also consisting of a pyrin domain as well as a caspase activation and recruitment domain (CARD); and (iii) pro-caspase-1 (Jha and Ting, 2009; Schroder et al., 2010b).

Inflammasome activity and production of IL-1β and IL-18 in monocytes and macrophages are tightly regulated via a two-step signal process. **Signal I** involves NF-κB- and/or AP-1-dependent up-regulation of the genes that encode for the various signalling components including NLRP3, pro-caspase-1, pro-IL-1β and pro-IL-18. **Signal II** involves the detection of PAMPs or DAMPs by NLRP3, and this in turn promotes the recruitment of ASC and pro-caspase-1 to the complex (Figure 3). The clustering of pro-caspase-1 at the inflammasome complex initiates its autocleavage into two subunits, p10 (10 kDa) and p20 (20 kDa), which heterodimerize to form the fully active caspase-1 enzyme (Schroder and Tschopp, 2010a).

**Evidence of a role for inflammasome activation in hypertension**

The consistent observation that levels of IL-1β and IL-18 are elevated in hypertension (Dalekos et al., 1997; Rabkin, 2009) might be taken as circumstantial evidence that the condition is associated with an increase in inflammasome-dependent caspase-1 activation. However, apart from a single study describing an increase in mRNA expression of pro-caspase-1 in the aorta and renal artery of spontaneously hypertensive rats compared with normotensive Wistar Kyoto rats (Chen et al., 1997), no studies have directly investigated whether...
hypertension is associated with inflammasome activation. In a genotype association analysis, Omi et al. (2006) showed that the incidence of a specific gain-in-function polymorphism of the NLRP3 gene was significantly higher in hypertensive than normotensive individuals. Furthermore, these authors described a gene–dose relationship whereby homozygotes for the polymorphism displayed higher BPs than heterozygotes (by 3 mmHg), who in turn displayed higher BPs than wild-type individuals (by 2 mmHg) (Omi et al., 2006).

If inflammasome activation is indeed a crucial determinant of hypertension, we are left with the question: what stimuli are responsible for inflammasome activation in the setting of hypertension? While we can presently only speculate on the nature of such stimuli, it is worth noting that hypertension is associated with increased levels of certain DAMPs that are often regarded as ‘classical’ activators of the NLRP3 inflammasome. These stimuli, which include microcrystals, high levels of extracellular ATP and ROS (Schroder and Tschopp, 2010a), are described in the succeeding paragraphs.

**Microcrystals**

There is a growing body of evidence that microcrystals can induce inflammasome activation, and may be implicated in the pathogenesis of various inflammatory diseases, including atherosclerosis and inflammatory lung diseases (Dostert et al., 2008; Duewell et al., 2010). Microcrystals, which range in size from 0.5 to 3.0 nm, form as a result of high concentrations of relatively insoluble solutes in the circulation and tissues. Microcrystals are detected by phagocytes and engulfed into the phagolysosome within the cell. However, the shard-like structures of many microcrystals rupture the lysosomal membrane, releasing its contents, including cathepsins and other proteolytic enzymes, into the cytosol. These lysosomal enzymes are thought to act as the triggers of inflammasome activation (Schroder et al., 2010b).

Monosodium urate crystals are known to trigger NLRP3 inflammasome activation, and thereby mediate inflammation associated with gout and pseudo-gout (Martinon et al., 2006). Importantly, a high serum level of urate (hyperuricaemia) is considered a risk factor for the development of hypertension (Ward, 1998; Bos et al., 2006). Studies dating back to the 19th century have reported a strong association between hyperuricaemia and hypertension (Haig, 1889; Bos et al., 2006). In support of a causal link between the two conditions, induction of mild hyperuricaemia in rats resulted in a marked increase in BP (Mazzali et al., 2001). Furthermore, clinical trials have shown that allopurinol, a drug used for the treatment of hyperuricaemia and gout, was highly effective at reducing BP in hypertensive adolescents, but less so in older individuals, suggesting that hyperuricaemia may have an especially important role early in the pathogenesis of hypertension (Feig et al., 2008). It remains to be determined whether microcrystal-induced inflammasome activation represents the mechanistic link between hyperuricaemia and elevated BP.

**Extracellular ATP**

Extracellular ATP acting at the P2X7 receptor is a well-described stimulus for NLRP3 inflammasome activation and there is evidence that this receptor might play a role in hypertension. In general, high levels of extracellular ATP occur as a consequence of cellular damage and a loss of plasma membrane integrity and thereby serve as a danger signal to the immune system (Trautmann, 2009). There is some controversy surrounding how ATP/P2X7 signalling actually leads to inflammasome assembly. The P2X7 receptor is a ligand-gated ion channel and initially it was thought that the K+ efflux that followed activation of this receptor represented the signal for inflammasome activation (Mariathasan et al., 2006). It has also been suggested that P2X7-dependent activation of inflammasomes may involve the recruitment of the pore-forming protein, pannexin-1, to the plasma membrane, in turn allowing the entry of DAMPs into the cell which are ultimately the stimuli for inflammasome activation (Schroder and Tschopp, 2010a). However, more recently, it was suggested that DAMPs, including microcrystals, are able to directly stimulate the release of endogenous ATP to cause IL-1β production in a P2X7-dependent mechanism (Riteau et al., 2012). Regardless, all of these possibilities involve a central role for the P2X7 receptor in inflammasome activation. In addition, expression of this receptor was elevated in various models of hypertension in rodents, and its deletion (i.e. in P2X7 receptor-knockout mice) is associated with lower BP and less renal fibrosis and inflammation (Vonend et al., 2004; Ji et al., 2012a,b).

**ROS**

It is clear that ROS and NF-κB play important roles in priming of the inflammasome (i.e. Signal I) to cause transcriptional up-regulation of NLRP3, pro-IL-1β and pro-IL-18 (Bauerfeind et al., 2009; 2011). However, the role of ROS in NLRP3 and caspase-1 activation (i.e. Signal II) still remains controversial. On the one hand, high levels of ROS have been shown to oxidatively modify caspase-1 protein resulting in a reduction in its catalytic activity (Meissner et al., 2008). Conversely, various DAMPs that are known to activate the NLRP3 inflammasome induce the production of ROS (Cruz et al., 2007; Dostert et al., 2008; Tschopp and Schroder, 2010). Furthermore, several studies have shown that inhibition of ROS can prevent ATP- and microcrystal-induced inflammasome activation (Dostert et al., 2008; Liao et al., 2013; Kojima et al., 2014) and it has thus been proposed that ROS (rather than microcrystals and extracellular ATP) are the actual triggers for assembly of the NLRP3 inflammasome (Schroder and Tschopp, 2010a).

It is well established that hypertensive stimuli, such as angiotensin II, aldosterone and endothelin-1, increase the expression and activity of a family of enzymes called NOX in both immune and non-immune cell types (Drummond et al., 2011; Touyz and Briones, 2011). NOX enzymes are considered primary sources of ROS and play key roles in physiological redox signalling and in the host-defense response to invading pathogens (Drummond et al., 2011). However, in the setting of hypertension, elevated NOX expression may lead to excessive ROS production, which can in turn result in oxidative modifications to other enzymes including endothelial NOS (eNOS), xanthine dehydrogenase and the subunits of the mitochondrial electron transport chain (Touyz and Schiffrin, 2004; Touyz and Briones, 2011). Such modifications uncouple these enzymes from their normal catalytic function and render them as additional enzymatic sources of ROS. In
inflammatory disease, rheumatoid arthritis (Mertens and Singh, 2009). Despite its short half-life and poor oral bioavailability (it must be administered subcutaneously), anakinra has been shown in clinical trials to be effective at reducing monocyte infiltration and inflammation in the synovial joints of patients with rheumatoid arthritis (Fleischmann et al., 2004).

Canakinumab is a high-affinity human monoclonal antibody against IL-1β (Kuemmerle-Deschner and Haug, 2013). It has a longer plasma half-life and more favourable safety profile than anakinra and is currently approved for clinical use in the treatment of cryopyrin-associated periodic syndrome—a rare inflammatory condition caused by a mutation in the NLRP3 gene (Kuemmerle-Deschner and Haug, 2013). In a Phase IIb trial on men and women with well-controlled diabetes and a high cardiovascular risk profile, canakinumab treatment for 4 months was shown to reduce circulating markers of inflammation including CRP, IL-6 and fibrinogen, without altering plasma lipid profiles (Ridker et al., 2012). Based on these promising findings, canakinumab was taken into a large multinational Phase III clinical trial [Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)], to investigate its effects on recurrent cardiovascular events such as myocardial infarction and stroke in patients with coronary artery disease and elevated levels of high-sensitivity CRP (Ridker et al., 2011). Results from this study are expected to be released in 2017 and it will be interesting to see what effects (if any) canakinumab treatment has on BP in these high risk patients.

**Caspase-1 inhibitors**

Caspase-1 has been a prime target for several inflammatory diseases including arthritis and inflammatory bowel disease (Randle et al., 2001). Because caspase-1 inhibition should block the production of both IL-1β and IL-18, it is reasonable to expect that inhibitors of this enzyme will be more efficacious than IL-1R antagonists at reducing inflammation. However, it is also conceivable that caspase-1 inhibitors might have more off-target effects than drugs that selectively target either IL-1β or IL-18 alone.

Ac-YVAD-cmk and ac-YVAD-CHO are tetrapeptides that specifically and irreversibly inhibit caspase-1. These inhibitors are highly selective for caspase-1 (K_i ~ 1 nM) over other caspase isoforms (K_i = 163 to more than 10 000 nM) (Rabuffetti et al., 2000). Moreover, several studies have shown that ac-YVAD inhibits caspase-1 activity in vivo, thereby reducing inflammation in experimental models of spinal cord injury and cerebral haemorrhage (Karaoglan et al., 2008; Suzuki et al., 2009; Wu et al., 2010). Several low MW caspase-1 inhibitors have also been developed and tested in clinical trials for the treatment of inflammatory conditions including rheumatoid arthritis, psoriasis and hepatitis C (Cornelis et al., 2007; MacKenzie et al., 2010). However, each of these trials were terminated either because of toxicity, especially with regard to liver function, or as a result of poor efficacy (MacKenzie et al., 2010). A clinical trial is currently underway to assess the effects of another caspase-1 inhibitor, VX-765, for the treatment of epilepsy (Kaminski et al., 2014). Post hoc analysis of data from this trial suggests that VX-765 decreased seizure frequency and that this effect was sustained for >2 weeks after treatment was discontinued (Kaminski...
some activation by facilitating K+ activation of P2X7 receptors is thought to induce inflammation. Rather, IL-1β is thought to contribute to epilepsy through directly enhancing NMDA receptor activity via a Src kinase-dependent mechanism (Viviani et al., 2003; Kaminski et al., 2014). It is unclear what effect this action of caspase-1 inhibition would have in terms of treatment of hypertension. On one hand, Src kinase activity is enhanced in VSMCs of spontaneously hypertensive rats and is thought to contribute to vascular remodelling associated with hypertension (Touyz et al., 2002). On the other hand, activation of NMDA receptors in the nucleus tractus solitarius (NTS) has been associated with a reduction in BP (Kubo and Kihara, 1988), and thus caspase-1-mediated inhibition of these receptors might be expected to worsen hypertension. Clearly, these issues, as well as those relating to toxicity, need to be resolved before caspase-1 inhibition can be considered as a therapeutic option for the treatment of hypertension.

P2X7 receptor antagonists

The P2X7 receptor is an ATP-gated ion channel that allows the passage of cations such as Na+, Ca2+ and K+ (Volonté et al., 2012; Alexander et al., 2013). It displays a restricted expression profile found primarily in macrophages, certain lymphocytes and fibroblasts (Carroll et al., 2009). As mentioned, activation of P2X7 receptors is thought to induce inflammation by facilitating K+ efflux and/or recruitment of the hemi-channel pannexin-1 and subsequent entry of DAMPs into the cell. A-438079 is a competitive reversible inhibitor of the P2X7 receptor that is at least 100-fold more selective for this receptor than other members of the P2 receptor family (Donnelly-Roberts and Jarvis, 2007). Of direct relevance to the present discussion, A-438079, as well as a structurally distinct inhibitor of P2X7 receptors, Brilliant Blue G, were shown to reduce urinary albumin excretion, macrophage infiltration and BP in a rat model of salt-sensitive hypertension (Ji et al., 2012a). These findings highlight the potential of P2X7 receptor antagonists as novel therapies for the treatment of hypertension.

Pleiotropic actions of statins

Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) are widely used in the clinic to reduce serum cholesterol levels – and thus cardiovascular risk – in patients with hypercholesterolaemia (Sirtori, 2014). However, in addition to cholesterol lowering, statins display pleiotropic effects that likely contribute to their beneficial effects on the cardiovascular system. Thus, statins have been shown to have modest antihypertensive effects, especially in patients with resistant hypertension (Borghi et al., 2000; Wassmann et al., 2001; Strazzullo et al., 2007; Briasoulis et al., 2013), and the ability to enhance endothelial function (Tsunekawa et al., 2001; de Jongh et al., 2002; Landmesser et al., 2005) and inhibit ROS production (Wassmann et al., 2001; Delbosc et al., 2002). In addition, statins possess anti-inflammatory properties such as reducing circulating levels of proinflammatory cytokines and suppressing adhesion molecule expression on vascular endothelial and smooth muscle cells (Albert et al., 2001; Chung et al., 2002; Rezaie-Majd et al., 2002). In a recent study, it was shown that treatment of bone marrow-derived macrophages from mice with statins interfered with the processing of pro-IL-1β (Davaro et al., 2014). Specifically, statin treatment was associated with the formation of a 28 kDa intermediate form of IL-1β, which came at the expense of production of the mature 17 kDa form. The partly processed form of IL-1β failed to induce IL-6 production in HEK 293T cells, indicating that it had no intrinsic agonistic activity. Furthermore, pretreatment of cells with the 28 kDa variant blocked the ability of mature IL-1β to stimulate cytokine production in the same assay, suggesting that it may be a novel IL-1RI antagonist. While these findings need to be confirmed in vivo in humans, it is tempting to speculate that inhibition of IL-1β processing may explain at least some of the pleiotropic actions of statins in reducing cardiovascular risk.

Conclusion

In summary, there is a growing body of evidence to suggest that hypertension is associated with elevated production of the IL-1 family cytokines, IL-1β and IL-18. At this stage, it is not known whether elevated levels of IL-1β and IL-18 are causes or mere consequences of chronically elevated BP and/or its disease sequelae such as vascular remodelling, atherosclerosis and renal dysfunction. It also remains to be determined whether inflammasome activation is involved and, if so, which stimuli are responsible. Several drugs that are currently in clinical use or undergoing trials for the treatment of other inflammatory disorders act by targeting different components of the inflammasome/IL-1 signalling pathway. Therefore, a better understanding of the activation mechanisms and role of inflammasome-derived IL-1 family cytokines in hypertension has a high potential to improve the way we manage the condition in the clinic.

Acknowledgements

This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; APP1062721) and the Group-of-Eight Australia (Go8)/German Academic Exchange Service (DAAD) Joint Research-Cooperation Scheme. G. R. D. and C. G. S. are supported by Senior Research Fellowships from the NHMRC of Australia (ID Nos. APP1006017 and 350327 respectively). S. M. K. is supported by a Monash Graduate Scholarship (ID No. 5129593). None of these funding sources had any role in the writing of the report or in the decision to submit the article for publication.

Conflict of interest

None.

References

Aly A, Palluy O, Favero J, Bonne C, Modat G, Dormand J (1992). Hypoxia/reoxygenation stimulates endothelial cells to promote...
interleukin-1 and interleukin-6 production. Effects of free radical scavengers. Agents Actions 37: 134–139.

Albert MA, Danielson E, Rifaï N, Ridker PM (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64–70.

Alexander SPH, Benson HE, Facenda E, Pawson AJ, Sharan JM, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676–1705.

Alexander SPH, Benson HE, Facenda E, Pawson AJ, Sharan JM, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459–1581.

Alexander SP, Benson HE, Facenda E, Pawson AJ, Sharan JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol 170: 1582–1606.

Andresen HO, Arakawa H, Dinarello CA, Utsunomiya M, Kuchner R, Karasawa M et al. (2006). The Concise Guide to PHARMACOLOGY 2006: Enzymes. Br J Pharmacol 148: 324–362.

Andresen HO, Arakawa H, Dinarello CA, Utsunomiya M, Kuchner R, Karasawa M et al. (2007). The Concise Guide to PHARMACOLOGY 2007: Ligand-gated ion channels. Br J Pharmacol 149: 245–304.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2009). The Concise Guide to PHARMACOLOGY 2009: Adenosine receptors. Br J Pharmacol 157: 1103–1137.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2010). The Concise Guide to PHARMACOLOGY 2010: Adenosine receptors. Br J Pharmacol 159: 635–669.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2011). The Concise Guide to PHARMACOLOGY 2011: Adenosine receptors. Br J Pharmacol 163: 1781–1810.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2012). The Concise Guide to PHARMACOLOGY 2012: Adenosine receptors. Br J Pharmacol 165: 281–313.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2013a). The Concise Guide to PHARMACOLOGY 2013: Adenosine receptors. Br J Pharmacol 169: 1773–1808.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2013b). The Concise Guide to PHARMACOLOGY 2013: Adenosine receptors. Br J Pharmacol 169: 2827–2861.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2013c). The Concise Guide to PHARMACOLOGY 2013: Adenosine receptors. Br J Pharmacol 169: 3872–4283.

Bauer S, Leibbrandt P, Balasubramanian R, Wollheim CB (2013d). The Concise Guide to PHARMACOLOGY 2013: Adenosine receptors. Br J Pharmacol 169: 5589–5602.
Dinarello CA (1996). Biologic basis for interleukin-1 in disease. Blood 87: 2095–2147.

Dinarello CA (2002). The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 (S Suppl. 27): S1–S13.

Donnelly-Roberts DL, Jarvis MF (2007). Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151: 571–579.

Dörffel Y, Lätsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR et al. (1999). Pretactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34: 113–117.

Dorfmueller P, Perros F, Balabanian K, Humbert M (2003). Inflammation in pulmonary arterial hypertension. Eur Respir J 22: 358–363.

Dorrance A (2007). Interleukin 1-beta (IL-1beta) enhances contractile responses in endothelium-denuded aorta from hypertensive, but not normotensive, rats. Vascul Pharmacol 47: 160–165.

Dostert C, Petrelli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674–677.

Drummond GR, Selemidis S, Griendling KK, Sobey CG (2011). Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453–471.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind F et al. (2010). NLRP3 inflammasomes are required for atherosclerosis and activated by cholesterol crystals. Nature 464: 1357–1361.

Feig DI, Soletsky B, Johnson RJ (2008). Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924–932.

Fleischmann R, Stern R, Iqbal I (2004). Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 4: 1333–1344.

Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U (2002). Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 195: 245–257.

Gordon S (2002). Pattern recognition receptors: doubling up for the innate immune response. Cell 111: 927–930.

Gu J-W, Tian N, Shparago M, Tan W, Bailey A, Manning R (2006). Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in resistance arteries. J Pharmacol Exp Ther 316: 43–47.

Haig A (1889). On uric acid and arterial tension. Br Med J 1: 288–291.

Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T et al. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857–865.

Haller H, Park JK, Dragun D, Lippoldt A, Luft FC (1997). Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension. Nephrol Dial Transplant 12: 899–903.

Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847–856.

Januzzi J (2013). ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 6: 493–500.

Jha S, Ting JP (2009). Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J Immunol 183: 7623–7629.

Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R et al. (2012a). P2X7(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 35: 173–179.

Ji X, Naito Y, Weng H, Endo K, Ma X, Iwai N (2012b). P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 303: F2107–F2115.

Jimenez-Alayo F, Brones AM, Giraldo J, Planas AM, Salaices M, Vila E (2006). Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in children with familial hypercholesterolemia. J Am Coll Cardiol 40: 2117–2121.

Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl F, Floege J et al. (1992). Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464–474.

de Jongh S, Lilien MR, op’t Roodt J, Stroes ES, Bakker HD, Kastelein JJ (2002). Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40: 2117–2121.

Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H et al. (2009). Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60: 3651–3662.

Kahlenberg JM, Dubyak GR (2004). Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release. J Leukoc Biol 76: 676–684.

Kaminski RM, Rogawski MA, Kiltgaard H (2014). The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurother 11: 385–400.

Kanneganti TD, Lamkanfi M, Nunez G (2007). Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549–559.

Karaoglan A, Kaya E, Akdemir O, Sagmanligil A, Bilguvar K, Cirakoglu B et al. (2008). Neuroprotective effects of Ac.VYAD.cmk on experimental spinal cord injury in rats. Surg Neurol 69: 561–567.

Kojima S, Negishi Y, Tsukimoto M, Takenouchi T, Kitani H, Takeda K (2014). Purinergic signaling via P2X receptor mediates IL-1beta production in Kupffer cells exposed to silica nanoparticle. Toxicology 321C: 13–20.

Kubo T, Kihara M (1988). Evidence of N-methyl-D-aspartate receptor-mediated modulation of the aortic baroreceptor reflex in the rat nucleus tractus solitarii. Neurosci Lett 87: 69–74.

Kuemmerle-Deschner JB, Haug I (2013). Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis 5: 315–329.
Labow M, Shuster D, Zetterstrom M, Nunes P, Terry R, Cullinan EB et al. (1997). Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 59: 2452–2461.

Lamkanf M, Dixit VM (2014). Mechanisms and functions of inflammasomes. Cell 157: 1013–1022.

Landmesser U, Bahlmann F, Mueller M, Speikermann S, Kirchhoff N, Schulz S et al. (2005). Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111: 2356–2363.

Latz E (2010). NOX-free inflammasome activation. Blood 116: 1393–1394.

Lee D, Leite R, Fleming C, Pollock J, Webb R, Brands M (2004). Hypertensive response to acute stress is attenuated in interleukin-6 knockout mice. Hypertension 44: 259–263.

Lee D, Sturgis L, Labazi H, Osborne J, Fleming C, Pollock J et al. (2006). Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H1935–H1940.

Levy BI (2004). Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109: 8–13.

Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP (2005). Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 355: 131–136.

Liao PC, Chao LK, Chou JC, Dong WC, Lin CN, Lin CY et al. (2013). Lipopolysaccharide/adenosine triphosphate-mediated signal transduction in the regulation of NLRP3 protein expression and caspase-1-mediated interleukin-1beta secretion. Inflamm Res 62: 89–96.

Loughrey JP, Laffey JG, Moore BJ, Lynch F, Boylan JF, McLoughlin P (2003). Interleukin-1 beta rapidly inhibits aortic endothelium-dependent relaxation by a DNA transcription-dependent mechanism. Crit Care Med 31: 910–915.

Lu X, Kakkar V (2014). Inflammasome and atherogenesis. Curr Pharm Des 20: 108–124.

MacKenzie SH, Schipper JL, Clark AC (2010). The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 13: 568–576.

Madej A, Okopien B, Kowalski J, Haberka M, Herman ZS (2005). Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep 57: 878–881.

Madhur M, Lob H, McCann L, Iwakura Y, Blinder Y, Guzik T et al. (2010). Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55: 500–507.

Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228–232.

Martinon F, Tschopp J (2004). Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561–574.

Martinon F, Tschopp J (2007). Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14: 10–22.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241.

Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al. (2001). Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101–1106.

Meissner F, Molawi K, Zychlinsky A (2008). Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol 9: 866–872.

Mertens M, Singh JA (2009). Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36: 1118–1125.

Mervaala EM, Müller DN, Park JK, Schmidt F, Lohn M, Breu V et al. (1999). Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33 (1 Pt 2): 389–395.

Miller A, Liew F (2011). The IL-33/ST2 pathway – a new therapeutic target in cardiovascular disease. Pharmacol Ther 131: 179–186.

Mills K, Dungan L, Jones S, Harris J (2013). The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 93: 489–497.

Miyachi K, Takiyama Y, Honjo Y, Tateno M, Haneda M (2009). Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGFBeta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83: 190–199.

Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A et al. (2000). NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (1 Pt 2): 193–201.

Nakamura S, Otani T, Okura R, Jijel Y, Motoda R, Kurimoto M et al. (2000). Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia 14: 1052–1059.

Omi T, Kumasaki T, Okuda H, Munktulga L, Yanagisawa Y et al. (2006). An intrinsic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet 14: 1295–1305.

O’Neill LA (2002). Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Curr Top Microbiol Immunol 270: 47–61.

Paiolini P (2001). Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep 3 (Suppl. 1): S3–S9.

Pauleto P, Rattazzi M (2006). Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 21: 850–853.

Pawson AJ, Sharman JL, Benson HE, Facenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098–1106.

Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T (2001). Pre-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 31: 31–36.

Pei C, Barbour M, Fairlie-Clarke K, Allan D, Mu R, Jiang H-R (2014). Emerging role of interleukin-33 in autoimmune diseases. Immunology 141: 9–17.

Petrilli V, Dostert C, Muruve DA, Tschopp J (2007). The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19: 615–622.
Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV et al. (2009). Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 106: 14948–14953.

Probstfeld J, O’Brien KD (2010). Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 105 (1 Suppl.): 10A–20A.

Rabkin SW (2009). The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 6: 192–199.

Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M (2000). Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 20: 4398–4404.

Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R (2001). ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 10: 1207–1209.

Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P et al. (2002). Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22: 1194–1199.

Ridker PM, Thuren T, Zalewski A, Libby P (2011). Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162: 597–605.

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J et al. (2012). Effects of interleukin-1B inhibition with canakinumab on hemoglobin A1C, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126: 2739–2748.

Riteau N, Baron L, Villere B, Guillou N, Savigny F, Ryffel B et al. (2012). ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. Cell Death Dis 3: e403.

Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ (2004). Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606–F616.

Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ (2012). Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol 39: 96–103.

Ross R (1999). Atherosclerosis – an inflammatory disease. N Engl J Med 340: 115–126.

Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J (2001). Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 158: 1743–1756.

Schroeder K, Tschopp J (2010a). The inflammasomes. Cell 140: 821–832.

Schroeder K, Zhou R, Tschopp J (2010b). The NLRP3 inflammasome: a sensor for metabolic danger? Science 327: 296–300.

Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K et al. (2003). Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31–38.

Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA (2001). IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98: 13249–13254.
Vonend O, Turner C, Chan C, Loesch A, Dell’Anna G, Srai K et al. (2004). Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 66: 157–166.

Wang Q, Zuo X-R, Wang Y-Y, Xie W-P, Wang H, Zhang M (2013). Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-kB pathway in rats. Vascul Pharmacol 58: 71–77.

Ward HJ (1998). Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352: 670–671.

Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W et al. (2001). HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450–1457.

Weir MR, Dzau VJ (1999). The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12 (12 Pt 3): 2055–2135.

Wen H, Ting J, O’Neill L (2012). A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? Nat Immunol 13: 352–357.

WHO (2013). The top 10 causes of death Vol. 2014: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed 2/3/2014).

Wolf BB, Green DR (1999). Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274: 20049–20052.

Wu B, Ma Q, Khatibi N, Chen W, Sozen T, Cheng O et al. (2010). Ac-YVAD-CMK decreases blood-brain barrier degradation by inhibiting caspase-1 activation of interleukin-Ibeta in intracerebral hemorrhage mouse model. Transl Stroke Res 1: 57–64.

Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y et al. (2005). Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25: 1458–1462.

Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J et al. (2009). NLRP3/cryopyrin is necessary for interleukin-Ibeta (IL-Ibeta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284: 12762–12771.

Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C et al. (2012). Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 59: 136–144.

Zhou MS, Schulman IH, Raji L (2010a). Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 28: 527–535.

Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010b). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136–140.